



- [2021 Immunization Updates: COVID-19, Influenza, and Meningococcal Disease](#) – September 2021
- [Drug Safety Communication: FDA Requests Removal of Pregnancy Contraindication for Statins](#) – August 2021
- [UPDATED: Drug Safety Communication: Voluntary Recall of Varenicline \(Chantix\) Due to Nitrosamine](#) – September 2021
- [Drug Safety Communication: Potential Increased Arrhythmia Risk from Lamotrigin](#) – April 2021
- [Clinical Review: Recommendations for the Tapering of Benzodiazepines](#) – March 2021
- [Clinical Review: Recommendations for the Management of Acute Dental Pain](#) – January 2021
- [Drug Safety Communication: Stronger Warning Labels for Benzodiazepines](#) – October 2020
- [2020 Immunization Updates: Vaccination during COVID-19, Flu, HepA, and Tdap](#) – September 2020
- [Clinical Review: 2020 Standards of Care for Treatment of Type 2 Diabetes](#) – August 2020
- [Clinical Guideline: Reproductive Health in Rheumatic and Musculoskeletal Diseases](#) – May 2020
- [Improving Quality of Care: Update of Risks Associated with Use of Fluoroquinolones](#) – April 2020
- [Drug Safety Communication: Withdrawal of All Ranitidine Products](#) – April 2020
- [Drug Safety Communication: Mental Health Side Effects from Montelukast](#) – March 2020
- [Improving the Quality of Care: Risks Associated with Use of Gabapentin](#) – December 2019
- [Alert: New Global Guidelines for the Treatment of Asthma](#) – October 2019
- [2019 Immunization Updates: Flu, HepA, HPV, Measles, CA School Requirements](#) – September 2019
- [Clinical Review Update: Concomitant Anticholinergic and Antipsychotic Use](#) – August 2019
- [Drug Safety Communication: Sleep Behavior Risks with Select Sleep Aids](#) – June 2019
- [Drug Safety Communication: Risks with Sudden Discontinuation of Opioids](#) – April 2019
- [Drug Safety Communication: Updated Adverse Effects from Fluoroquinolones](#) – March 2019
- [Clinical Review Update: Morphine Equivalent Daily Dose](#) – February 2019
- [Alert: New Naloxone Regulations Effective on January 1, 2019](#) – January 2019
- [2018 Immunization Updates: Flu, Tdap, HepB, Zoster, MMR, Adult Vaccines](#) – September 2018
- [Alert: Mandatory Use of CURES 2.0 Begins October 2, 2018](#) – September 2018

- [Drug Safety Communication: Adverse Effects from Fluoroquinolone Antibiotics](#) – July 2018
- [ProDUR Update: Additive Toxicity Alert Now Focused Only On CNS Depressants](#) – July 2018
- [In the Pharmacy: Pharmacists Furnishing Nicotine Replacement Products](#) – March 2018
- [Drug Safety Communication: New Age Limit for Opioid Cough and Cold Medicines](#) – February 2018
- [Alert: Online Report to the Vaccine Adverse Event Reporting System \(VAERS\)](#) – September 2017
- [2017 Immunization Updates: Influenza, HepA, Meningococcal, HPV, Adult Vaccines](#) – September 2017
- [Clinical Review: Drug-Induced QT Interval Prolongation](#) – August 2018
- [Drug Safety Communication: Risks of Codeine and Tramadol Use in Children](#) – May 2017
- [Improving the Quality of Care: Overutilization of Proton Pump Inhibitors](#) – April 2017
- [Alert: Medi-Cal Expands Access to Adult Immunizations in Pharmacies](#) – April 2017
- [Improving the Quality of Care: Risks Associated with Use of Fluoroquinolones](#) – February 2017
- [2016 Immunization Updates: Influenza, Meningococcal, Tdap, Hib, Rotavirus](#) – September 2016
- [Clinical Review: The Treatment of Opioid Addiction with Buprenorphine](#) – August 2016
- [Clinical Review: Atypical Antipsychotics and Adverse Metabolic Effects](#) – April 2016
- [Drug Safety Communication: Saxagliptin, Alogliptin and Risk of Heart Failure](#) – April 2016
- [Drug Safety Communication: New Safety Warnings Added to Prescription Opioids](#) – April 2016
- [Alert: California Upgrades Prescription Drug Monitoring Program to CURES 2.0](#) – January 2016
- [Improving the Quality of Care: Updated Guidelines for Migraine Prevention](#) – February 2013